MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Sponsored by Penumbra, Inc.
The Role of the Continuous Power Aspiration System in Myocardial Perfusion and Prevention of No Reflow
With Irene Marthe Lang, MD; Stefano Galli, MD; Juan F. Iglesias, MD, FESC, FACC; and Yazan Musayeb, MD
Concept’s Abluminus NP Polymer-Free DES and Antiplatelet Strategies Studied in STARS-DAPT
January 23, 2026—Concept Medical Inc., announced the enrollment of the first patients in the STARS DAPT randomized controlled trial (RCT) of ST-segment elevation myocardial infarction (STEMI) treated with the company’s Abluminus np—a polymer-free, sirolimus-based, nanocarrier eluting stent—and a P2Y12 inhibitor-based single antiplatelet strategy after a short dual antiplatelet therapy (DAPT) versus conventional DAPT.
Biotronik’s Orsiro DES for STEMI Evaluated at 5-Years in BIOSTEMI
October 26, 2023—Biotronik announced that 5-year data from the BIOSTEMI trial confirmed the superiority of the company’s Orsiro drug-eluting stent (DES) versus a durable polymer everolimus-eluting stent (DP-EES) for patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
MedAlliance’s SELUTION DeNovo Study Enrolls First of 3,300 Patients to Compare Sirolimus DEB Versus DES
August 31, 2021—MedAlliance announced the enrollment of the first patient in the coronary randomized controlled SELUTION DeNovo study of the company’s Selution SLR sirolimus drug-eluting balloon (DEB) versus a limus drug-eluting stent (DES).
BIOMAG-II Study of Biotronik’s Freesolve RMS Begins Enrollment
May 13, 2024—Biotronik announced the enrollment of the first patient in the BIOMAG-II trial.
Biotronik's Pantera Pro Coronary Balloon Catheter Launched in Europe
April 1, 2015—Biotronik announced the European market launch of its Pantera Pro coronary balloon dilatation catheter.
